Combination Therapy Extends Survival in Patients with Severe Heart Disease
A groundbreaking study shows that combining valve replacement with targeted drug therapy significantly improves survival in patients with severe heart conditions, including aortic stenosis and cardiac amyloidosis.
Recent research conducted by an international consortium led by MedUni Vienna and University College London has revealed promising advancements in treating severe heart conditions, particularly in patients suffering from both aortic stenosis and cardiac amyloidosis. Traditionally, treatments focused solely on mechanical interventions such as valve replacement, leaving the amyloid deposits in the heart muscle often untreated. However, the new study demonstrates that a combined approach—integrating aortic valve replacement with targeted drug therapy for amyloidosis—significantly improves patient survival rates.
The study analyzed data from 226 patients across ten countries, all diagnosed with both aortic stenosis and cardiac amyloidosis. Aortic stenosis involves the narrowing of the heart valve, obstructing blood flow from the heart's left ventricle into the circulation. Cardiac amyloidosis occurs when misfolded proteins deposit in the heart tissue, impairing its function. Both conditions predominantly affect older adults and frequently coexist.
Importantly, the research shows that patients receiving both valve replacement and tafamidis, a drug used to treat amyloidosis, had notably better survival outcomes. In fact, those who underwent both treatments displayed long-term survival rates similar to patients with aortic stenosis alone without amyloidosis. This underscores the importance of comprehensive treatment strategies.
The findings advocate for routine screening for amyloidosis in patients with severe aortic stenosis. Recognizing the co-occurrence enables healthcare providers to administer targeted therapies that can prolong life and improve quality of life. Early detection and combined treatment are crucial in managing these complex, age-related cardiac diseases.
Overall, this research highlights the potential to change clinical practice by emphasizing the importance of diagnosing and treating both conditions concurrently, paving the way for better patient outcomes in severe heart disease cases.
Source: https://medicalxpress.com/news/2025-06-combination-therapy-prolong-life-severe.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Generation X Faces Higher Risk of Methamphetamine-Related Deaths in Australia
Australia's Generation X faces a worrying rise in methamphetamine-related deaths, with recent research highlighting gaps in support services and the impact of stigma on treatment access. Learn more about this concerning trend and its implications.
The Impact of Lifelong Social Connections on Molecular Aging and Health
Strong, lifelong social connections can slow biological aging by influencing epigenetic and inflammatory pathways, promoting healthier aging and longevity.
AI Chatbots in Healthcare: Outperforming Doctors in Diagnosis but Requiring Safeguards Against Overprescribing
Emerging AI chatbots are outperforming doctors in diagnosis but pose risks of overprescribing and inequality. Responsible deployment with safeguards is crucial for safe healthcare innovation.
Genetic DNA Patterns Enhance Diagnosis and Risk Assessment in Childhood Leukemia
New research reveals that DNA methylation pattern analysis can improve diagnosis and risk assessment in childhood leukemia, allowing for more personalized treatments and fewer side effects.